Current WorkWe are currently working on bringing two products to market - KindaPed™ anti-head lice treatment and Ryboquin® cancer therapy
KindaPed™ anti-head lice treatment
EctoPharma successfully brought the KindaPed™ head lice product through all its stages from early research and development to market readiness. It is an excellent example of the company’s business model in action. Having completed its work, EctoPharma out-licensed the UK rights to the product to Thornton & Ross, established leaders in the UK head lice market, who launched the product on to the market as “Hedrin Treat & Go” in July 2011.
EctoPharma is in active discussions with potential partners in other parts of the world, principally North America and China.
In addition, the company believes the product represents a significant step forward in the treatment of several common problems found in agricultural regions around the world. These include treating crops against the devastating effects of aphids and greenfly. In addition, we are encouraged by the findings of recent studies into the efficacy of KindaPed™ against red mites in chickens and cat ear mites, demonstrating 80-90% efficacy rates.
For more information on KindaPed™, please go to the PRODUCTS section of this website
Ryboquin® cancer therapy
Advanced R&D work is underway into a novel gene therapy employing cutting edge nano technology which, we believe, may have the potential to boost the treatment of several forms of cancer. This work takes EctoPharma into one of the most exciting and important of all human health arenas. We plan to launch a Phase 1 trial in 2013. We intend to progress the project to a successful conclusion of Phase II trials before seeking a partner to join us in taking the product on to the market.
For more information on Ryboquin®, please go to the PRODUCTS section of this website.